Description
It is estimated that 80 million adults in the US suffer from obesity.
mechanism of action
contains an active component called liraglutide, which is a glucagon-like peptide-1 (GLP-1) analogue. The drug, which can be administered intravenously, reaches activated neurons in brain regions and regulates the appetite and calorie intake.
contains an active component called liraglutide, which is a glucagon-like peptide-1 (GLP-1) analogue. The drug reaches activated neurons in brain regions, and regulates appetite and calorie intake."
Clinical trials on
The FDA's approval of was based on results from three Phase III clinical trials, known as SCALE (Satiety and Clinical Adiposity−Liraglutide Evidence in Nondiabetic and Diabetic people) studies, which were conducted for 56 weeks to evaluate the drug's safety and efficacy.
- Saxenda
- Ozempic
- Saxenda Pen
- Liraglutide injection
Production Capacity:
222222
Delivery Timeframe:
Immediate
Incoterms:
Not informedPackaging Details:
Not informed
More about
hebei Eminent technology co.,ltd
10-50
Employees
500K - 1M
Sales volume (USD)
100%
% Export sales
Year
Established
Business type
- Industry / Manufacturer
- Representative / Agent
- Distributor / Wholesaler
Keywords
- 玻尿酸
- 蛋白线
- 美容产品
Contact and location
- youki liu
- +86 xxxxxxxx
- shijiazhuang / | China